Successful immunotherapeutic approaches for lymphoma, such as the anti-CD20 antibody rituximab in combination with chemotherapy, are also less effective in high-grade B-cell lymphomas displaying MYC rearrangements [14,15,16], suggesting the involvement of MYC in tumor escape from novel immunotherapeutic approaches. This evidence concerns the gene MYC and lymphoma.